Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TERN-601 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| TERN-601 | DRUG | Investigational drug |
| Matching Placebo | OTHER | Matching placebo |
TERN-601 is an investigational small molecule being developed for the treatment of overweight or obesity. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities. The drug is intended for adults with overweight or obesity, as evaluated in a completed clinical study.
TERN-601 is being developed by Terns Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol TERN. The company is conducting clinical research to evaluate the safety, efficacy, and tolerability of TERN-601 in adults with overweight or obesity.
TERN-601 is in Phase 2 clinical development. A Phase 2 study has been completed, but the drug remains investigational and has not received FDA approval. It is still in clinical development for the treatment of overweight or obesity.
TERN-601 has one completed Phase 2 clinical trial with the identifier NCT06854952. The study, titled 'A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity,' enrolled 167 participants. The trial was uncontrolled and not randomized or double-blinded.
TERN-601 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for overweight or obesity. A Phase 2 study has been completed, but the drug has not yet received marketing approval from the FDA or any other regulatory authority.